Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (September 2017)

29 slides from Sorrento Therapeutics's investor presentation, September 2017

  1. Slide 1: Corporate Presentation

    Corporate Presentation September, 2017 V092117

  2. Slide 2: Disclaimer

    Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in th

  3. Slide 3: Sorrento Antibody Centric Immuno-Oncology Platform

    Sorrento Antibody Centric Immuno-Oncology Platform Bi-Specific mAbs © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 3

  4. Slide 4: I/O Strategic Approach (Tic Tac Toe)

    I/O Strategic Approach (Tic Tac Toe) SRNE active MM projects Effective monotherapies (Multiple Myeloma) Multimodal synergistic potential Multiple Myeloma Modality and Target Matrix Exponential asset value (combination therapy) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 4

  5. Slide 5: Financial Opportunity

    Financial Opportunity Historical Deal Values for Multiple Myeloma Modalities (1) Janssen-GenMab (2) Amgen-Xencor (3) Celgene-EngMab (4) Celgene-Sutro (5) Celgene-BlueBird (6) Celgene-Inhibrx (7) Celgene-AstraZeneca (8) Pfizer-Merck © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 5

  6. Slide 6: Immuno-Oncology Core Program Pipeline

    Immuno-Oncology Core Program Pipeline Key I/0 Programs IND enabling Phase 1 Phase 2 Phase 3 NDA submission CD38 CAR-T (Multiple Myeloma) * CEA CAR-T (Metastatic Liver Tumors) * CD38 ADC * CMET ADC PDL1 Seprehvir® (Solid Tumors) * Combination therapies (synergistic potential under evaluation) * Progr

  7. Slide 7: CD38 Franchise: CD38 as Target for CAR-T Immunotherapy of MM

    CD38 Franchise: CD38 as Target for CAR-T Immunotherapy of MM › Type II transmembrane glycoprotein with cyclic ADP ribose hydrolase activity › Widely found on the surface of lymphoid and myeloid lineages including B, T, NK cells and macrophages o Expression on B, T, NK cells, and the common myeloid p

  8. Slide 8: Sorrento's Anti-CD38 mAb Has Different Binding Epitope from Daratumumab

    Sorrento’s Anti-CD38 mAb Has Different Binding Epitope from Daratumumab CD38A2 binds to an epitope on CD38 that is different from Daratumumab as evident by signal increase 3) Wash 4) CD38A2 binding to captured CD38 2) CD38 captured by Daratumumab 1) Daratumumab immobilized on chip © 2017 Sorrento Th

  9. Slide 9: Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma

    Anti-CD38 CAR-T Program For Treatment of Multiple Myeloma Anti-CD38 CAR-T Cells Selectively Kill CD38 High Expression Cells © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 9

  10. Slide 10: Anti-CD38 CAR-T Cells In Xenograft Mouse Model

    Anti-CD38 CAR-T Cells In Xenograft Mouse Model (RPMI8226 MM Tumors) Untreated Mice T-007 Treated › On Day -23, immunodeficient NSG mice were Prior to treatment infused with human RPMI8226 MM tumor cells › On Day 0, CAR-T cells were administered i.v. 1 week after treatment › In all treated mice, the

  11. Slide 11: ADC CD38-129 for Multiple Myeloma (Daudi Cells)

    ADC CD38-129 for Multiple Myeloma (Daudi Cells) D a u d i- lu c D a y 4 8 10 12 10 11 T o t a l F lu x [ p /s ] 10 10 10 9 10 8 10 7 10 6 10 5 g g g g S /k /k /k /k B g g g g P m m m m 4 4 4 4 0 0 .0 .0 .0 .0 0 0 0 0 9 4 9 4 2 1 2 1 -1 -3 -1 -3 8 8 8 8 3 3 3 3 D D D D C C C C At 0.04 mg/kg the ADC C

  12. Slide 12: ADC CD38-136 for Multiple Myeloma (Daudi Cells)

    ADC CD38-136 for Multiple Myeloma (Daudi Cells) D a u d i- lu c D a y 4 8 10 12 10 11 T o t a l F lu x [ p /s ] 10 10 10 9 10 8 10 7 10 6 10 5 10 4 g g g g S /k /k /k /k B g g g g P m m m m 4 .4 .4 4 .0 .0 0 0 0 0 6 6 6 8 3 6 3 -2 -1 8 -1 -2 8 8 8 3 3 8 3 D D 3 D C C D C C At 0.4 mg/kg the ADC CD38-

  13. Slide 13: STAT3 iTAb Antitumor Activity

    STAT3 iTAb (internalizing Targeting Antibody) Antitumor Activity © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 13

  14. Slide 14: Seprehvir: Next-Generation HSV-1 based Oncolytic Virus Immunotherapy

    Seprehvir: Next-Generation HSV-1 based Oncolytic Virus Immunotherapy ➢ HSV-1 immuno-oncolytic therapy with 100+ patients treated to date ➢ 5 Phase I Trials: High Grade Glioma, SCCHN, melanoma, mesothelioma, pediatric neuroblastoma/osteosarcoma ➢ Well tolerated, no toxicity and expected AEs have been

  15. Slide 15: Combination SEPREHVIR / Anti-PD-1 Antibody Prolongs Survival

    Combination SEPREHVIR / Anti-PD-1 Antibody Prolongs Survival in M3-9-M Rhabdomyosarcoma Model PBS/CTRL PBS/anti-PD1 SEPREHVIR/PBS SEPREHVIR/anti-PD1 Combination therapy of Seprehvir and anti-PD1 mAb exhibits potent anti-tumor activity © 2017 Sorrento Therapeutics, Inc. All Rights Reserved Scientific

  16. Slide 16: Pain Strategic Approach: The 'Hard Wired' System

    Pain Strategic Approach: The ‘Hard Wired’ System Non-Opioids (Progressive) Nociceptive Pain Caused by activity in neural pathways in response to potentially tissue-damaging stimuli (Intractable) Neuropathic Pain Initiated or caused by primary lesion or dysfunction in the nervous system © 2017 Sorren

  17. Slide 17: Non-Opioid Pain Management Core Pipeline

    Non-Opioid Pain Management Core Pipeline Key Pain Programs IND enabling Phase 1 Phase 2 Phase 3 NDA submission ZTlido™ (1.8% lidocaine patch) - relief of pain associated w ith PHN RTX (resiniferatoxin) - terminal cancer pain - intrathecal route (NIH) RTX (resiniferatoxin) - terminal cancer pain - ep

  18. Slide 18: ZTlido Next Generation Lidocaine Patch

    ZTlido™ Next Generation Lidocaine Patch NDA submission complete. PDUFA response expected by 02/28/18 © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 18

  19. Slide 19: ZTlido Mean Plasma Lidocaine Concentration

    ZTlido™ Next Generation Lidocaine Patch Linear Plot of Mean Plasma Lidocaine Patch 1.8% Concentration vs Time with Physical Exercise and Normal Conditions 100 Mean Plasma Lidocaine Concentration (ng/mL) 80 60 40 Normal conditions Exercise conditions 20 0 0 5 10 15 20 25 30 35 40 45 50 Time (Hours) ©

  20. Slide 20: Sorrento's Resiniferatoxin (RTX) for Non-Opioid Control of Intractable Pain

    Sorrento’s Resiniferatoxin (RTX) for Non-Opioid Control of Previously Intractable Pain o Ultrapotent, highly specific TRPV1 agonist that selectively and permanently ablates afferent neurons (“molecular neurolysis”). o Targeted single injection via epidural (EP), intrathecal (IT) or regional (IA, IP,

  21. Slide 21: Pain (Resiniferatoxin): Novel Class Potent TRPV1 Agonist

    Pain (Resiniferatoxin): Novel Class Potent Transient Receptor Vanilloid-1 Agonist (TRPV1A) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 21

  22. Slide 22: Pain (Resiniferatoxin): Novel Class Potent TRPV1 Agonist

    Pain (Resiniferatoxin): Novel Class Potent Transient Receptor Vanilloid-1 Agonist (TRPV1A) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 22

  23. Slide 23: Pain (Resiniferatoxin): Canine Validation Studies - Osteosarcoma

    Pain (Resiniferatoxin): Canine Validation Studies (translational to humans) Osteosarcoma pain (single intrathecal administration) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved Brown et al, Anesthesiol 2005 23

  24. Slide 24: Pain (Resiniferatoxin): Canine Validation Studies - Arthritis

    Pain (Resiniferatoxin): Canine Validation Studies (translational to humans) Open Label Study (7 dogs with OA pain). Arthritis pain (single intra-articular injection) • Intra-articular RTX application (10mcg). • Day 7 assessment, pain interference and pain severity scores significantly improved (CBPI

  25. Slide 25: Sorrento's Resiniferatoxin (RTX) for Pain Control (Human Studies)

    Sorrento’s Resiniferatoxin (RTX) for Pain Control (Human Studies) o Phase 1B – Terminal Cancer Pain (intrathecal administration) NIH Phase I Study (intrathecal administration) • NIH collaboration, open-label, dose escalation safety study, >6/10 NRS (severe pain) and Pain not controlled by standard T

  26. Slide 26: Sorrento Strategic Vision (Executive Summary)

    Sorrento Strategic Vision (Executive Summary) Immuno-Oncology Strategy: Build successful cancer treatments through proprietary multimodal multipronged therapeutic approaches › Acquire novel and promising immuno-oncology assets › Enhance and develop monotherapy assets from early stage to clinical val

  27. Slide 27: Sorrento's Rich Technology Asset Base (Executive Summary)

    Sorrento’s Rich Technology Asset Base (Executive Summary) Immuno-Oncology Platform Non-Opioid Pain Management Key Technology Assets Key Technology Assets Key Technology Assets › Extensive library of fully human antibodies (G-MAB™) › CAR-T therapy › TRPV1 Agonist - Neuron Ablating Agent (resiniferato

  28. Slide 28: Sorrento's Senior Leadership Team

    Sorrento’s Senior Leadership Team Name Position(s) Name Position(s) Chairman, President Senior Vice President of Immunotherapy, Henry Ji, Ph.D. Gunnar F. Kaufmann, Ph.D. & Chief Executive Officer Head of Research and Global Partnerships Jerome B. Zeldis, M.D., Chief Medical Officer Mark Brunswick, P

  29. Slide 29: Contact

    (858) 203-4100 4955 Directors Place, San Diego, CA 92121 [email protected] © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 29

Sorrento Therapeutics — Investor Presentation (September 2017) on 6ix